Cosentyx subcutaneous — Medica
Non-Radiographic Spondyloarthritis
Preferred products
- Enbrel
- adalimumab-adbm
- Cyltezo
- adalimumab-adaz
- adalimumab-ryvk
- Simlandi
- Otezla
- Skyrizi subcutaneous (pen or syringe)
- Sotyktu
- Stelara subcutaneous
- Taltz
- Tremfya subcutaneous
- Rinvoq
- Rinvoq LQ
- Xeljanz
- Xeljanz XR
- Cimzia
Initial criteria
- Patient meets the standard Inflammatory Conditions – Cosentyx Subcutaneous Prior Authorization Policy criteria
Reauthorization criteria
- Patient continuing therapy meets the standard Inflammatory Conditions – Cosentyx Subcutaneous Prior Authorization Policy criteria
Approval duration
initial therapy as directed or 1 year for continuing therapy